TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01550276

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: All patients were assessed in the same conditions before the treatment, after the treatment (at 4 weeks), and at follow-up (after 8 weeks). Four treatment sessions (one session per week). Prior to each treatment session, the physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.~The SI treatment aims to release the suboccipital muscle spasm10 that maintains the occiput-atlas-axis joint dysfunction. This technique, which was administered for 10 minutes, uses a deep and progressive gliding pressure applied with the fingertips towards the posterior arch of atlas.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: All patients were assessed in the same conditions before the treatment, after the treatment (at 4 weeks), and at follow-up (after 8 weeks). Four treatment sessions (one session per week). Prior to each treatment session, the physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.~The OAA manipulation was bilaterally administered and it attempts to restore the motion dysfunction of this complex. It is a structural technique performed on a vertical line along the odontoid process of axis; neither flexion nor extension is used, and lateroflexion is minimal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: All patients were assessed in the same conditions before the treatment, after the treatment (at 4 weeks), and at follow-up (after 8 weeks). Four treatment sessions (one session per week). Prior to each treatment session, the physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.~The combination of both treatments aims to determine whether this combination has greater effects than the separate application of each treatment. After receiving the treatment, the subjects in the experimental groups stayed for five minutes in the supine resting position, in neutral ranges of cervical flexion, extension, lateral flexion and rotation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: All patients were assessed in the same conditions before the treatment, after the treatment (at 4 weeks), and at follow-up (after 8 weeks). Four treatment sessions (one session per week). Prior to each treatment session, the physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.~The control group received four sessions of placebo treatment, followed by ten minutes of resting position.
Study: NCT01211561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selenium, selenomethionine
Description: Patients will receive one 200 ug pill of Selenomethionine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Patients will be given one 200 ug placebo pill each day for 6 months
Study: NCT02005744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501
Description: CKD-501 0.5mg, PO(per oral), once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501
Description: CKD-501 0.5mg, PO(per oral), once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501
Description: CKD-501 0.5mg, PO(per oral), once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501
Description: CKD-501 0.5mg, PO(per oral), once
Study: NCT00797719

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-op RT +/- chemotherapy
Description: Patients on the study will receive IMRT for approximately 1 week of 5 daily treatments. Short pre-operative hemithoracic RT is a new technique. 1 week post-RT, they will proceed with an extrapleural pneumonectomy. If the mediastinal lymph nodes that are removed during surgery are positive for tumour cells, 3 cycles of chemotherapy, consisting of raltitrexed and cisplatin, will be given 6-12 weeks post-surgery.
Study: NCT00615576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-656933
Description: SB-656933 will be available as white film coated, round tablet and will be available in strengths of 50 milligrams, administered orally once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo tablet to visually match the SB-656933 tablet will also be supplied, administered orally once daily.
Study: NCT03792516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: artesunate ointment 40%
Description: artesunate formulated as an ointment to be applied topically to the vulva

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: artesunate ointment 40%
Description: artesunate formulated as an ointment to be applied topically to the vulva

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: artesunate ointment 40%
Description: artesunate formulated as an ointment to be applied topically to the vulva
Study: NCT01440764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Study: NCT02005406

Intervention type: DEVICE
Intervention: Experimental group and control groupl
Description: JET
Study: NCT02773693

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy-Cognitive Only (CPT)
Description: Twice weekly CPT over 6 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy-Cognitive Only (CPT)
Description: Twice weekly CPT over 6 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy-Cognitive Only (CPT)
Description: Twice weekly CPT over 6 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy of Insomnia and Nightmares (CBTin)
Description: Cognitive behavioral therapy of insomnia and nightmares weekly over 6 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy of Insomnia and Nightmares (CBTin)
Description: Cognitive behavioral therapy of insomnia and nightmares weekly over 6 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Continuation Cognitive Processing Therapy-Cognitive Only (CPT)
Description: Once weekly continuation CPT over 6 weeks.
Study: NCT00687713

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: 150mg for the first 3 days of dosing. Increased to 150 mg b.i.d until taper.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04954638

Intervention type: OTHER
Intervention: endodontic desinfection
Description: * outcome assessment of the retreatment of endodontically treated teeth presenting chronic apical periodontitis~* effectiveness of hyperpure chlorine dioxide compared with sodium hypochloride~* using microbiological methods~* outcome assessed by radiological method and clinical evaluation

Intervention type: OTHER
Intervention: endodontic desinfection
Description: * outcome assessment of the retreatment of endodontically treated teeth presenting chronic apical periodontitis~* effectiveness of hyperpure chlorine dioxide compared with sodium hypochloride~* using microbiological methods~* outcome assessed by radiological method and clinical evaluation
Study: NCT04372316

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylcobalamin
Description: methylcobamin injection 8 weeks or tablet 8 weeks， followed by 24 weeks methylcobamin tablet until 32 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylcobalamin
Description: methylcobamin injection 8 weeks or tablet 8 weeks， followed by 24 weeks methylcobamin tablet until 32 weeks
Study: NCT01873313

Intervention type: DRUG
Intervention: Ropivacaine
Study: NCT03976570

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational Therapy
Description: Occupational therapy to children with subthreshold attention deficit hyperactivity disorder
Study: NCT00486018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab injection 0.3 mg
Description: Ranibizumab injection 0.3 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab injection 0.5 mg
Description: Ranibizumab injection 0.5 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: Sham injection in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six sham injections.
Study: NCT00554775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: PO 100 mg daily during WBRT, increasing to 150mg daily after WBRT for up to 24 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: WBRT plus matched placebo for the same schedule and duration as erlotinib hydrochloride
Study: NCT02328222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESW group
Description: CORTICOSTEDORID TREATMENT WAS AS FOLLOWS: day zero post-transplantation (DP 0), 500 mg/day of MPD; (DP 1), 250 mg MPD; (DP 2), 125 mg MPD; (DP 3), 60 mg MPD; (DP 4), 30 mg MPD; and (DP 5), PREDNISONE AS DOSES 1 MG/KG (1 MONTH) AND A REDUCTION TO ACHIEVE 0.1 MG/KG IN THE 3rd MONTH.
Study: NCT04149886

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cardiac ganglion plexus ablation(cardioneuroablation)
Description: Cardiac ganglion plexus ablation in the left atrium will be performed before implanting permanent pacemaker in patients with sick sinus syndrome.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Permanent pacemaker implantation
Description: DDD permanent pacemaker will be implanted in the paticipants.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Permanent pacemaker implantation
Description: DDD permanent pacemaker will be implanted in the paticipants.
Study: NCT03567941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet orally administered under fasting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet orally administered under fasting

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet orally administered under fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Tablet orally administered under fasting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodon bitartrate-acetaminophen arm 1
Description: Tablet orally administered under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodon bitartrate-acetaminophen arm 1
Description: Tablet orally administered under fasted conditions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydrocodon bitartrate-acetaminophen arm 1
Description: Tablet orally administered under fasted conditions
Study: NCT02630836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XCEL-MT-OSTEO-BETA
Description: XCEL-MT-OSTEO-BETA followed by endomedullary nailing

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgical treatment
Description: Isolated endomedullary nailing

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Description: Isolated endomedullary nailing
Study: NCT01700049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vismodegib (150 mg PO daily)
Description: Biopsies will be performed on all participants at baseline, week 12 and week 24.
Study: NCT01425333

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery for ovarian endometrioma
Description: Patients undergoing surgery for ovarian endometrioma

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery for ovarian endometrioma
Description: Patients undergoing surgery for ovarian endometrioma
Study: NCT02857738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 987519
Description: Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPF 15 Control
Description: Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
Study: NCT00306150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trasylol (Aprotinin, BAYA0128)
Description: Subjects will be randomized to receive an infusion of aprotinin (a test dose followed by a loading dose of 2 million KIU before skin incision followed by 500,000 KIU/hour until the end of surgery) or matching placebo. The maximal dose of aprotinin, that can be administered is 7,000,000 KIU, regardless of the duration of the operation. When a total of 7 million has been reached the administration of aprotinin must be discontinued.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is used according to the description of Arm 1
Study: NCT00000569

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triamcinolone
Description: 1200 micrograms of triamcinolone in daily divided doses

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00903448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prilosec OTC (omeprazole-magnesium)
Description: Prilosec OTC (omeprazole-magnesium 20.6 mg) tablet to be taken with a glass of water prior to breakfast

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prevacid
Description: Prevacid (15 mg lansoprazole) capsule to be taken with a glass of water prior to breakfast
Study: NCT05124197

Intervention type: OTHER
Intervention: prone position
Description: extension of prone position duration
Study: NCT01630213

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 + fish oil/fish oil placebo
Description: Vitamin D3 2000 IU/day and fish oil (840 mg of omega 3-fatty acids; Omacor)/fish oil placebo per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3 placebo + fish oil/fish oil placebo
Description: Vitamin D3 placebo/day + fish oil (840 mg of omega 3-fatty acids; Omacor)/fish oil placebo/day
Study: NCT04111406

Intervention type: DRUG
Group type: OTHER
Intervention: Current practice
Description: Epidural insertion and epidural drug administration depend on anesthetist in charge

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Protocol based
Description: Epidural insertion and epidural drug administration depend on anesthetist in research team using protocol based~1. insertion at mid-level of surgical insertion~2. insertion depth is 3-5 cm in space, not more than 5 cm~3. using benzoin tincture and transparent dressing to fix catheter~4. test dose with 2%xylocaine with adrenaline 1:200,000 3ml If not cover desired dermatome: 2% lidocaine with adr added 3 ml every 5 min (up to 2 times)~5. After induction and patients' hemodynamic are stable. Load 2 mg morphine with 0.0625% bupivacaine + morphine 0.02 mg/ml 3 ml then continuous infusion with rate according to initial local anesthetic requirement for incisional area coverage
Study: NCT02715206

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: keepin' it REAL classic
Description: keepin' it REAL consists of 10 classroom lessons implemented in 7th grade and 4 booster sessions implemented in 8th grade by the classroom teacher following training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: keepin' it REAL rural
Description: keepin' it REAL rural drug prevention curriculum consists for 10 lessons taught in 7th grade and 4 booster sessions taught in 8th grade.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: control
Description: control group continues to teach whatever prevention curriculum they were using prior to study
Study: NCT00703573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-777469 400 mg
Description: S-777469 400 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-777469 800 mg
Description: S-777469 800 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo BID
Study: NCT02135653

Intervention type: RADIATION
Intervention: Radiotherapy

Intervention type: RADIATION
Intervention: Radiotherapy

Intervention type: OTHER
Intervention: Eischens Yoga
Study: NCT01839630

Intervention type: DRUG
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: sorafenib treatment (including dose, duration, modification) and TACE procedure are decided by the investigator
Study: NCT01567748

Intervention type: PROCEDURE
Intervention: BP Measurements at aorta, radial and femoral locations
Description: The following additional research related procedures will be performed in patients recruited into the study: 1) a small cuff will be placed on one the finger of each subject to measure the pulse in the finger (Finapres); 2) a cannula will be placed in the femoral artery by the surgeon to measure femoral artery pressure; 3) for a period of two minutes immediately before and after the cardiopulmonary bypass a small cannula (the size of a pencil tip) will be inserted by the surgeon under direct vision into the aorta and 4) the information from each of these cannula will be recorded on a computer for later study.
Study: NCT00626314

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: myoblast
Description: autologous myoblast

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: sham
Description: sham injection procedure
Study: NCT05221424

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Education
Description: The training program about hypertension prepared according to the Roy Adaptation Model was performed in a room in the cardiology outpatient clinic of a state hospital. The training content was shaped according to 4 (four) basic areas of the Roy Adaptation Model (physiological field, self-concept field, role function field and interdependence field). The training taught to each patient individually and interactively with the support of powerpoint presentation lasted for averagely 45-50 minutes. A Hypertension Training Booklet was prepared according to the Roy Adaptation Model in order to be used during the training and to strengthen the training.
Study: NCT01642199

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reduced Intensity Behavioral Weight Loss + Peer Health Coach
Description: Participants will receive a 12-month reduced intensity group behavioral weight loss program. During weeks that there are no group meetings, participants will be coached by peers (i.e., other members of their weight loss group).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reduced Intensity Behavioral Weight Loss + Mentor Health Coach
Description: Participants will receive a 12-month reduced intensity group behavioral weight loss program. During weeks that there are no group meetings, participants will be coached by a mentor (i.e., successful weight loser).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reduced Intensity Behavioral Weight Loss
Description: Participants will receive 12 months of a reduced intensity group behavioral weight loss program.
Study: NCT03690882

Intervention type: OTHER
Intervention: systematic review of medical imaging
Study: NCT01957228

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone biopsies
Study: NCT03248453

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CoPS
Description: The COPS is an automated and objective computer-based program which generate a score/number after the colonoscope has reached the cecum. The participants are able to compare the score with experts.
Study: NCT01196078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib [Tarceva]
Description: 150 mg, orally once a day for up to 6 cycles of 21 days each

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vinorelbine
Description: 60 mg/m2, orally on days 1 and 8 of cycle 1, 80 mg/m2 for the other cycles
Study: NCT02881060

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01802749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated liposomal doxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Study: NCT03567941

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocodon bitartrate-acetaminophen arm 1
Description: Tablet orally administered under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodon bitartrate-acetaminophen arm 2
Description: Tablet orally administered under fed conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodon bitartrate-acetaminophen arm 2
Description: Tablet orally administered under fed conditions
Study: NCT04538430

Intervention type: DEVICE
Group type: OTHER
Intervention: SPRINT percutaneous peripheral nerve stimulator placed
Description: Placement of a SPRINT percutaneous peripheral nerve stimulator targeting the bilateral medial branches at the suspected level of pain generation. This procedure is done as standard of care.
Study: NCT01728909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Nasal Spray
Description: 40 IU of the saline nasal spray will be administered once at the beginning of the visit.